Prakt. lékáren. 2005; 1(2): 100-102

Aplikační systémy pro léčení onemocnění vnitřního oka

doc. PharmDr. Ruta Masteiková CSc
VFU, Brno

Onemocnění vnitřního oka se nemůže až na výjimky léčit topickou nebo systémovou aplikací léčiv. V současné době existuje řada terapeutických systémů umožňujících dodání léčiv do sklivce a zadních segmentů oka. Řadíme mezi ně oční implantáty (Vitrasert®, Retisert®, Surodex® aj.), oční injekce (Retaane®, Macugen®, Lucentis®), přípravky pro fotodynamickou terapii (Visudyne®) nebo systémy pro oční iotoforézu (Eyegate®, Ocuphor®, Visulex®). Některé z nich jsou již přístupné na farmaceutickém trhu, u jiných probíhají klinické zkoušky.

Keywords: Klíčová slova: oční implantáty, oční injekce, fotodynamická terapie, oční iontoforéza.

Published: January 1, 2006  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Masteiková R. Aplikační systémy pro léčení onemocnění vnitřního oka. Praktické lékárenství. 2005;1(2):100-102.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Halbal M, et al. Iontophoresis: from the lab to the bed side. Exper Eye Res 2004; 78: 751-757. Go to original source... Go to PubMed...
    2. InnoRx Sustained Release System: Sustained Release Implant for Intraocular Drug Delivery. Surmodics, Inc. 2005. 4 p.
    3. Kodama M, et al. Effects of a new dexamethasone-delivery system (Surodex) on experimental intraocular inflammation models. Graefe's Arch Clin Exp Ophthalmol 2003; 241: 927-933. Go to original source... Go to PubMed...
    4. Michels S. Rosenfeld PJ. Treatment of neovascular age-related macular degeneration with Ranibizumab/Lucentis(TM). Klin Monatsbl Augenh 2005; 222: 480-484. Go to original source... Go to PubMed...
    5. Moshfeghi AA, Puliafito CA. Pegaptanib sodium for the treatment of neovascular age-related macular degeneration. Expert Opin Inv Drug 2005; 14: 671-682. Go to original source... Go to PubMed...
    6. Parkinson TM, et al. Tolerance of ocular iontophoresis in healthy volunters. J Ocul Pharmacol Ther 2003; 19: 145-151. Go to original source... Go to PubMed...
    7. Slakter JS, et al. Baseline characteristics of a phase 3 clinical study of anecortave acetate 15 mg in patients with exudative age-related macular degeneration (AMD). Invest Ophth Vis Sci 2005; 46 (Suppl): 1374.
    8. Stivastava SK. Pathological findings in eyes with the ganciclovir implant. Ophthalmology 2005; 112: 780-786. Go to original source... Go to PubMed...
    9. Strong HA. The Visudyne registry database: Collecting data from patients treated with verteporfin therapy for CNV due to AMD. Invest Ophth Vis Sci 2004; 45 (Suppl 2): U74.
    10. Terry A, et al. Thermally Labile Liposomes for Treatment of Blinding Retinal Disease. Drug Deliv Technol 2003; 3: http://www.drugdeliverytech.com. 22. 7. 2005.

    Return to the content


    Pharmacy for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.